Lead Product Candidate LB1148
LB1148
Lead Product Candidate LB1148
Our lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function. LB1148 is being investigated in a Phase 2 study to evaluate its effects on post-operative ileus and intra-abdominal adhesions and return of gastrointestinal function in subjects undergoing elective bowel resection.
LB1148 Highlights
LB1148: Granted FDA Fast Track Designation for Two Indications
- Reduction of the formation of intra-abdominal adhesions following abdominal or pelvic surgery; and
- Treatment of postoperative GI dysfunction (which may present as feeding intolerance, ileus, necrotizing enterocolitis, etc.) associated with gut hypoperfusion injury in pediatric patients who underwent congenital heart disease repair surgery.
Abdominal Adhesions are a Significant Medical Burden
Post Operative Bowel Function is a Big Bottleneck
- Patients generally do not leave the hospital until having a bowel movement
- Delayed bowel movement causes prolonged hospital stays and increased costs